Nobel Prize in Medicine awarded to three scientists for optogenetics research

The Nobel Assembly at the Karolinska Institute in Stockholm announced the winners on Monday, kicking off Nobels week. The three scientists will share a prize of 12 million Swedish kronor (about $1.718 million or £901,500).

Karl Deisseroth is based at Stanford University and the Howard Hughes Medical Institute in the United States. Peter Hegemann is at Humboldt University of Berlin, and Georg Nagel at the University of Würzburg in Germany.

The Nobel committee said optogenetics "is now being used in laboratories around the world to reveal the brain's mysteries" and has unravelled the pathways that lead to behaviour and disease.

The research began with Hegemann exploring how a single-celled type of green algae can swim toward light. He and Nagel discovered a protein that, when illuminated by blue light, opens a channel to create an electrical impulse. Putting that protein into other cells makes them light-sensitive. Deisseroth then worked with the gene that controls that protein to create a light-controlled switch for nerve cells in the brains of living mice.

The 2026 award is the 117th time the prize has been given. Out of the 235 laureates including the latest winners, only 14 have been women. Last year's prize went to three scientists researching the immune system.

Monday's medicine prize is followed by the physics prize on Tuesday, chemistry on Wednesday, literature on Thursday, the peace prize on Friday, and the Nobel Memorial Prize in Economic Sciences on October 12.

Analysis

Why This Matters

Optogenetics allows researchers to precisely control neural activity with light, transforming the study of brain disorders such as Parkinson's disease, depression, and epilepsy.
The technique is already used worldwide in laboratories, accelerating fundamental neuroscience discoveries that could lead to new therapies.
The prize highlights the growing importance of interdisciplinary research combining biology, physics, and engineering.

Background

Optogenetics emerged from basic research on how microorganisms respond to light. The three laureates' work over the past two decades built a technology that lets scientists insert light-sensitive proteins into specific neurons and activate them with flashes of light. This has become a standard tool in neuroscience, enabling experiments that were previously impossible. The Nobel Prize in Medicine has a history of recognising transformative techniques, such as CRISPR gene editing and immune checkpoint inhibitors.

Key Perspectives

Laureates: Their decades of collaborative and independent research created a new field. Deisseroth's application of the protein channel to mammalian neurons was the critical step that turned a biological curiosity into a practical tool. Neuroscience community: Optogenetics has been called a revolution because it delivers millisecond-precision control over specific cells, far beyond what electrical stimulation or drugs can achieve. Critics: Some raise ethical questions about potential misuse for neural control in humans, and technical challenges remain in translating the method to clinical treatments safely.

What to Watch

Announcement of the 2026 Nobel Prize in Physics on Tuesday, and Chemistry on Wednesday, to see if related fields are recognised.
Clinical trials using optogenetics to restore vision or treat neurological conditions; the prize may accelerate investment and regulatory attention.
Debate over broadening the technique for non-invasive applications in humans, which could raise new safety and ethical questions.